Alliancebernstein L.P. Invests $32.74 Million in Metsera Inc. $MTSR

Key Points

• Alliancebernstein L.P. acquired a substantial stake of 1,202,952 shares in Metsera Inc. valued at approximately $32.7 million, representing 1.15% ownership as of the latest reporting period.
• Metsera's stock has seen a 2.1% increase, trading at $37.25, with a significant 52-week range between $12.30 and $47.40.
• Several analysts have upgraded Metsera's ratings recently, with target prices ranging from $50 to $77, indicating a positive outlook, while one firm downgraded it from "hold" to "sell."

Alliancebernstein L.P. bought a new position in shares of Metsera Inc. (NASDAQ:MTSR - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 1,202,952 shares of the company's stock, valued at approximately $32,744,000. Alliancebernstein L.P. owned 1.15% of Metsera at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the stock. RA Capital Management L.P. purchased a new position in Metsera during the first quarter worth about $18,388,000. Braidwell LP purchased a new position in Metsera during the first quarter worth about $4,764,000. Paradigm Biocapital Advisors LP purchased a new position in Metsera during the first quarter worth about $32,432,000. Siren L.L.C. purchased a new position in Metsera during the first quarter worth about $4,083,000. Finally, Alpha Wave Global LP purchased a new position in Metsera during the first quarter worth about $64,894,000.

Analysts Set New Price Targets

MTSR has been the topic of a number of research reports. Guggenheim increased their target price on shares of Metsera from $56.00 to $62.00 and gave the stock a "buy" rating in a report on Tuesday, June 10th. Wells Fargo & Company began coverage on shares of Metsera in a research report on Friday, June 20th. They issued an "overweight" rating and a $65.00 price target for the company. Bank of America raised their price target on shares of Metsera from $45.00 to $50.00 and gave the company a "buy" rating in a research report on Thursday, August 28th. Cantor Fitzgerald reissued an "overweight" rating on shares of Metsera in a research report on Wednesday, September 3rd. Finally, Leerink Partnrs raised shares of Metsera to a "strong-buy" rating in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating and six have given a Buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $63.50.

Metsera Stock Down 3.0%

Metsera stock traded down $1.11 during trading on Friday, reaching $36.14. The stock had a trading volume of 1,076,861 shares, compared to its average volume of 1,037,552. Metsera Inc. has a 52-week low of $12.30 and a 52-week high of $47.40. The business has a 50 day moving average price of $35.37 and a 200 day moving average price of $28.81.

Metsera (NASDAQ:MTSR - Get Free Report) last issued its quarterly earnings data on Monday, July 28th. The company reported ($0.66) earnings per share for the quarter.

Metsera Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.